{"id":70754,"date":"2026-05-12T10:43:33","date_gmt":"2026-05-12T10:43:33","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70754"},"modified":"2026-05-21T07:14:10","modified_gmt":"2026-05-21T07:14:10","slug":"mazdutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/mazdutide\/","title":{"rendered":"Mazdutide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Mazdutide?<\/h3>\n<p style=\"margin: 0;\"><strong>Mazdutide<\/strong> (v\u00fdvojov\u00e9 k\u00f3dy IBI362 \/ LY3305677) je dlouhodob\u011b p\u016fsob\u00edc\u00ed dvojit\u00fd agonista receptor\u016f GLP-1 a glukagonu vyvinut\u00fd spole\u010dnost\u00ed Innovent Biologics (licencovan\u00fd od Eli Lilly). Jde o prvn\u00ed dvojit\u00fd agonista GLP-1\/glukagonu, kter\u00fd dos\u00e1hl f\u00e1ze 3 klinick\u00fdch studi\u00ed u obezity a diabetu 2. typu, p\u0159i\u010dem\u017e slo\u017eka glukagonu p\u0159id\u00e1v\u00e1 mechanismus v\u00fddeje energie nad r\u00e1mec toho, co produkuj\u00ed pouze GLP-1 nebo dvojit\u00e9 peptidy GLP-1\/GIP. Polo\u010das v plazm\u011b umo\u017e\u0148uje t\u00fddenn\u00ed d\u00e1vkov\u00e1n\u00ed. Dod\u00e1v\u00e1 se v lyofilizovan\u00fdch lahvi\u010dk\u00e1ch o s\u00edle 5 mg a 10 mg v\u00fdhradn\u011b pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdzkumn\u00e9 lyofilizovan\u00e9 peptidy \u00b7 HPLC \u010distota \u226599% (COA na vy\u017e\u00e1d\u00e1n\u00ed) \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava peptid\u016f \u00b7 1,400+ ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifikace<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS \u010d\u00edslo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2376247-09-1 (mazdutide; b\u011b\u017en\u011b uv\u00e1d\u011bno)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Typ<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Dlouhodob\u011b p\u016fsob\u00edc\u00ed dvojit\u00fd agonista receptor\u016f GLP-1 \/ glukagonu (acylovan\u00fd syntetick\u00fd peptid; Innovent IBI362 \/ Eli Lilly LY3305677; odvozen\u00fd od oxyntomodulinu)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4 865 Da (s acylac\u00ed mastnou kyselinou; publikovan\u00e1 zral\u00e1 forma)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Struktura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Syntetick\u00fd peptid zalo\u017een\u00fd na p\u0159irozen\u00e9 struktu\u0159e oxyntomodulinu (endogenn\u00edho dvojit\u00e9ho agonisty GLP-1\/glukagonu) s upraven\u00fdmi substitucemi pro odolnost v\u016f\u010di DPP-4 a p\u0159ipojenou mastnou diacylovou skupinou na lysinov\u00fd zbytek p\u0159es \u03b3-Glu spojku. Acylov\u00fd \u0159et\u011bzec zp\u016fsobuje reverzibiln\u00ed vazbu na s\u00e9rov\u00fd albumin, co\u017e prodlu\u017euje polo\u010das na t\u00fdden.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item11<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00fd pr\u00e1\u0161ek (b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item13<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC ov\u011b\u0159eno, COA na vy\u017e\u00e1d\u00e1n\u00ed)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Skladov\u00e1n\u00ed<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00e9: 2\u20138 \u00b0C (lednice) pro pracovn\u00ed z\u00e1sobu; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch vialek. Rekonstituovan\u00e9: 2\u20138 \u00b0C, pou\u017eijte do ~30 dn\u016f. Chra\u0148te p\u0159ed sv\u011btlem. Nefreeze\u2013thaw rekonstituovan\u00fd roztok.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Rozpustnost<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bakteriostatick\u00e1 voda (doporu\u010deno) nebo steriln\u00ed voda pro krat\u0161\u00ed dobu pou\u017eit\u00ed. Acylovan\u00e9 peptidy se mohou rozpou\u0161t\u011bt pomaleji \u2014 ponechte v\u00edce \u010dasu na vyrovn\u00e1n\u00ed.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pouze pro v\u00fdzkum<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Co je Mazdutide?<\/h2>\n<p><strong>Mazdutide<\/strong> je dlouhodob\u011b p\u016fsob\u00edc\u00ed syntetick\u00fd dvojit\u00fd agonista receptor\u016f GLP-1 a glukagonu vyvinut\u00fd pod v\u00fdvojov\u00fdmi k\u00f3dy IBI362 (Innovent Biologics, licencov\u00e1no od Eli Lilly LY3305677). Jde o jeden z nejpokro\u010dilej\u0161\u00edch slou\u010denin v nov\u00e9 vln\u011b farmakologie dvojit\u00fdch agonist\u016f odvozen\u00fdch od oxyntomodulinu \u2014 p\u0159\u00edstup odli\u0161n\u00fd jak od programu pouze GLP-1 (semaglutid), tak od programu dvojit\u00e9ho agonisty GLP-1\/GIP (tirzepatid). Strukturn\u00ed inspirac\u00ed je samotn\u00fd oxyntomodulin, 37-aminokyselinov\u00fd produkt zpracov\u00e1n\u00ed preproglukagonu ve st\u0159evn\u00edch L-bu\u0148k\u00e1ch, kter\u00fd p\u0159irozen\u011b aktivuje jak receptory GLP-1, tak glukagonu. Endogenn\u00ed oxyntomodulin m\u00e1 velmi kr\u00e1tkou farmakokinetiku; mazdutide to \u0159e\u0161\u00ed mastnou acylovou skupinou na lysinov\u00e9m zbytku, kter\u00e1 zp\u016fsobuje reverzibiln\u00ed vazbu na s\u00e9rov\u00fd albumin a prodlu\u017euje polo\u010das v plazm\u011b dostate\u010dn\u011b pro t\u00fddenn\u00ed subkut\u00e1nn\u00ed pod\u00e1n\u00ed v klinick\u00e9m v\u00fdzkumu.<\/p>\n<p>Mazdutide m\u00e1 zralou molekulovou hmotnost p\u0159ibli\u017en\u011b 4 865 Da v\u010detn\u011b acylov\u00e9 modifikace. Strukturn\u00ed kostra zachov\u00e1v\u00e1 dvojitou farmakologii receptor\u016f oxyntomodulinu, zat\u00edmco upraven\u00e9 substituce zaji\u0161\u0165uj\u00ed odolnost v\u016f\u010di proteolytick\u00e9mu \u0161t\u011bpen\u00ed zprost\u0159edkovan\u00e9mu DPP-4, kter\u00e9 by jinak vedlo k rychl\u00e9mu clearance. Mazdutide je hlavn\u00edm \u010d\u00ednsk\u00fdm metabolick\u00fdm peptidov\u00fdm programem, p\u0159i\u010dem\u017e studie f\u00e1ze 3 (GLORY-1 u obezity, DREAMS-1 a DREAMS-2 u diabetu 2. typu) uv\u00e1d\u011bj\u00ed sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti p\u0159ibli\u017en\u011b o 15\u201317 % v nejvy\u0161\u0161\u00ed d\u00e1vkov\u00e9 \u00farovni po 48 t\u00fddnech. Mimo \u010c\u00ednu mazdutide nen\u00ed <strong>FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. V\u00fdzkumn\u00fd DSIP prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n<\/strong> schv\u00e1len FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm z\u00e1padn\u00edm regul\u00e1torem. V \u010c\u00edn\u011b byl mazdutide schv\u00e1len NMPA pod svou po\u010d\u00e1te\u010dn\u00ed komer\u010dn\u00ed zna\u010dkou \u2014 \u010d\u00edm\u017e se stal jedn\u00edm z prvn\u00edch dvojit\u00fdch agonist\u016f inkretinov\u00fdch peptid\u016f, kter\u00e9 z\u00edskaly regula\u010dn\u00ed schv\u00e1len\u00ed pro lidsk\u00e9 pou\u017eit\u00ed kdekoli na sv\u011bt\u011b. V\u00fdzkumn\u00fd mazdutide prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n <strong>ur\u010den pouze pro laboratorn\u00ed v\u00fdzkum<\/strong> a nen\u00ed ur\u010den pro lidsk\u00e9 ani veterin\u00e1rn\u00ed pod\u00e1v\u00e1n\u00ed. Pro trojit\u00fd agonista, kter\u00fd p\u0159id\u00e1v\u00e1 GIP k t\u00e9to kombinaci GLP-1\/glukagonu, viz n\u00e1\u0161 <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> produktovou str\u00e1nku.<\/p>\n<h2>Mechanismus \u00fa\u010dinku \u2014 Dvojit\u00fd agonismus receptor\u016f GLP-1 \/ glukagonu<\/h2>\n<p>Co \u010din\u00ed mazdutide mechanicky v\u00fdjime\u010dn\u00fdm mezi sou\u010dasn\u00fdmi dvojit\u00fdmi agonistick\u00fdmi metabolick\u00fdmi peptidy, je to, \u017ee spojuje kanonickou osu sytosti\/glyk\u00e9mie GLP-1 s <strong>osou v\u00fddeje energie receptoru glukagonu<\/strong> \u2014 nikoli osu receptoru GIP, kterou vyu\u017e\u00edv\u00e1 tirzepatid. Dvojit\u00fd receptorov\u00fd profil vytv\u00e1\u0159\u00ed komplement\u00e1rn\u00ed \u00fa\u010dinky nap\u0159\u00ed\u010d t\u0159emi hlavn\u00edmi kompartmenty, jak dokl\u00e1d\u00e1 publikovan\u00fd v\u00fdzkum:<\/p>\n<ul>\n<li><strong>Aktivace receptoru GLP-1 \u2014 sytost, sekrece inzulinu \u03b2-bu\u0148kami, vyprazd\u0148ov\u00e1n\u00ed \u017ealudku<\/strong> \u2014 Mazdutid aktivuje receptor GLP-1 na beta-bu\u0148k\u00e1ch pankreatu (gluk\u00f3za-dependentn\u00ed sekrece inzul\u00ednu), POMC neuronech hypotalamick\u00e9ho j\u00e1dra arcuatus (centr\u00e1ln\u00ed signalizace sytosti) a vag\u00e1ln\u00edch aferentech \u017ealudku (zpomalen\u00e9 vyprazd\u0148ov\u00e1n\u00ed \u017ealudku). Tato slo\u017eka se p\u0159ekr\u00fdv\u00e1 s mechanismem semaglutidu a GLP-1 komponentou tirzepatidu a retatrutidu.<\/li>\n<li><strong>Aktivace receptoru glukagonu \u2014 energetick\u00fd v\u00fddej, mobilizace jatern\u00edch lipid\u016f, aktivace hn\u011bd\u00e9 tukov\u00e9 tk\u00e1n\u011b<\/strong> \u2014 Charakteristick\u00fdm rysem mazdutidu je simult\u00e1nn\u00ed aktivace receptoru glukagonu. Agonismus glukagonov\u00e9ho receptoru m\u00edrn\u011b zvy\u0161uje klidov\u00fd energetick\u00fd v\u00fddej, podporuje jatern\u00ed oxidaci mastn\u00fdch kyselin a mobilizaci lipid\u016f ze steatotick\u00fdch jater a podle publikovan\u00fdch studi\u00ed na hlodavc\u00edch p\u0159isp\u00edv\u00e1 k aktivaci hn\u011bd\u00e9 tukov\u00e9 tk\u00e1n\u011b. Komponenta energetick\u00e9ho v\u00fddeje odli\u0161uje multiagonisty obsahuj\u00edc\u00ed glukagon (mazdutid, retatutid, survodutid) od \u00fa\u010dink\u016f na t\u011blesnou hmotnost u \u010dist\u00fdch GLP-1 a dualn\u00edch GLP-1\/GIP peptid\u016f \u2014 tyto zp\u016fsobuj\u00ed \u00fabytek hmotnosti t\u00e9m\u011b\u0159 v\u00fdhradn\u011b sn\u00ed\u017een\u00edm energetick\u00e9ho p\u0159\u00edjmu, zat\u00edmco agonist\u00e9 s glukagonem p\u0159id\u00e1vaj\u00ed slo\u017eku metabolick\u00e9ho v\u00fddeje.<\/li>\n<li><strong>Rovnov\u00e1ha receptorov\u00e9 aktivity a \u201cglukagonov\u00fd paradox\u201d<\/strong> \u2014 Farmakologickou v\u00fdzvou u ko-agonismu glukagonov\u00e9ho receptoru je dosa\u017een\u00ed p\u0159\u00edzniv\u00e9ho \u010dist\u00e9ho \u00fa\u010dinku: samotn\u00fd glukagon zvy\u0161uje gluk\u00f3zu stimulac\u00ed jatern\u00ed produkce gluk\u00f3zy, co\u017e by glykemickou kontrolu sp\u00ed\u0161e zhor\u0161ilo. GLP-1 komponenta mazdutidu p\u0159eb\u00edj\u00ed glukagonem indukovan\u00fd \u00fa\u010dinek na gluk\u00f3zu dominantn\u00edm hypoglykemizuj\u00edc\u00edm p\u016fsoben\u00edm na inzul\u00edn a supres\u00ed glukagonu v beta- a alfa-bu\u0148k\u00e1ch, zat\u00edmco glukagonov\u00e1 slo\u017eka zachov\u00e1v\u00e1 v\u00fdhody mobilizace lipid\u016f a energetick\u00e9ho v\u00fddeje. Relativn\u00ed potence receptor\u016f GLP-1 v\u016f\u010di glukagonu je navr\u017eena tak, aby podporovala \u010dist\u00fd hypoglykemizuj\u00edc\u00ed \u00fa\u010dinek \u2014 d\u016fle\u017eit\u00fd rozd\u00edl oproti troj\u00edm agonist\u016fm jako <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">retatrutide<\/a> kde p\u0159isp\u00edv\u00e1 tak\u00e9 GIP.<\/li>\n<\/ul>\n<p>Mastn\u011b-kyselinov\u00e1 acylov\u00e1 vazba p\u0159ipojen\u00e1 k lysinov\u00e9 reziduu reverzibiln\u011b v\u00e1\u017ee cirkuluj\u00edc\u00ed s\u00e9rov\u00fd albumin, \u010d\u00edm\u017e vytv\u00e1\u0159\u00ed plazmatick\u00e9 depo, kter\u00e9 prodlu\u017euje \u00fa\u010dinn\u00fd polo\u010das a umo\u017e\u0148uje t\u00fddenn\u00ed subkut\u00e1nn\u00ed d\u00e1vkov\u00e1n\u00ed v klinick\u00e9m v\u00fdzkumu. Subkut\u00e1nn\u00ed pod\u00e1n\u00ed je standardn\u00ed v\u00fdzkumnou cestou. Mechanismus prodlou\u017een\u00e9ho uvol\u0148ov\u00e1n\u00ed je analogick\u00fd syst\u00e9mu C18 mastn\u00e9 kyseliny semaglutidu a C20 mastn\u00e9 kyseliny tirzepatidu, ale s odli\u0161nou d\u00e9lkou \u0159et\u011bzce a spojovac\u00ed chemi\u00ed p\u0159izp\u016fsobenou dual-receptorov\u00e9 farmakologii mazdutidu.<\/p>\n<h2>Publikovan\u00e9 v\u00fdzkumn\u00e9 aplikace<\/h2>\n<p>Mazdutid se pou\u017e\u00edv\u00e1 v laboratorn\u00edm v\u00fdzkumu zam\u011b\u0159en\u00e9m na:<\/p>\n<ul>\n<li><strong>V\u00fdzkum obezity a t\u011blesn\u00e9ho slo\u017een\u00ed<\/strong> \u2014 preklinick\u00e9 modely DIO hlodavc\u016f, t\u011blesn\u00e9 slo\u017een\u00ed (DEXA\/MRI), testy p\u0159\u00edjmu potravy, respira\u010dn\u00ed kvocient a klidov\u00fd energetick\u00fd v\u00fddej; kanonick\u00fd v\u00fdzkumn\u00fd peptid dualn\u00edho GLP-1\/glukagonu<\/li>\n<li><strong>Preklinick\u00fd v\u00fdzkum diabetu 2. typu<\/strong> \u2014 glykemickou kontrolu, n\u00e1hradn\u00ed markery HbA1c, dynamiku suprese glukagonu, inzulinovou senzitivitu u model\u016f hlodavc\u016f s vysokotu\u010dnou dietou a db\/db; p\u0159\u00edm\u00e9 srovn\u00e1n\u00ed s jednoduch\u00fdmi agonisty GLP-1 a dualn\u00edmi GLP-1\/GIP kompar\u00e1tory<\/li>\n<li><strong>MASLD\/MASH (metabolicky asociovan\u00e9 jatern\u00ed onemocn\u011bn\u00ed)<\/strong> \u2014 obsah jatern\u00edch triglycerid\u016f, ALT\/AST, staging fibr\u00f3zy; zvl\u00e1\u0161tn\u00ed z\u00e1jem kv\u016fli lipid-mobilizuj\u00edc\u00ed aktivit\u011b glukagonov\u00e9 slo\u017eky ve steatotick\u00fdch j\u00e1trech<\/li>\n<li><strong>V\u00fdzkum energetick\u00e9ho v\u00fddeje<\/strong> \u2014 m\u011b\u0159en\u00ed klidov\u00e9ho energetick\u00e9ho v\u00fddeje, aktivace hn\u011bd\u00e9 tukov\u00e9 tk\u00e1n\u011b, exprese termogenick\u00fdch gen\u016f; mechanistick\u00e1 anal\u00fdza glukagonem \u0159\u00edzen\u00e9 metabolick\u00e9 slo\u017eky<\/li>\n<li><strong>Srovn\u00e1vac\u00ed v\u00fdzkum du\u00e1ln\u00edch agonist\u016f<\/strong> \u2014 p\u0159\u00edm\u00e9 srovn\u00e1n\u00ed s alternativn\u00edm du\u00e1ln\u00edm agonistou <a href=\"https:\/\/medsbase.com\/cs\/tirzepatide\/\">Tirzepatide<\/a> (GLP-1\/GIP) a troj\u00edm agonistou <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> (GLP-1\/GIP\/glukagon); v\u00fdzkum strategie vrstven\u00ed receptor\u016f<\/li>\n<li><strong>V\u00fdzkum kardiovaskul\u00e1rn\u00edch a ren\u00e1ln\u00edch \u00fa\u010dink\u016f<\/strong> \u2014 \u00fa\u010dinky na krevn\u00ed tlak, lipidov\u00e9 profily, progresi ateroskler\u00f3zy u ApoE<sup>-\/-<\/sup> modely; nov\u011b vznikaj\u00edc\u00ed datov\u00e1 sada vzhledem k f\u00e1zi 3 v\u00fdvoje mazdutidu<\/li>\n<li><strong>Farmakologie glukagonov\u00e9 osy<\/strong> \u2014 charakterizace izolovan\u00e9 farmakologie glukagonov\u00e9ho receptoru, dynamika jatern\u00ed gluk\u00f3zov\u00e9 produkce, rovnov\u00e1ha mezi supres\u00ed glukagonu a agonismem glukagonu u molekul du\u00e1ln\u00edch agonist\u016f<\/li>\n<li><strong>Srovn\u00e1vac\u00ed v\u00fdzkum inkretin\u016f<\/strong> \u2014 srovn\u00e1n\u00ed s monoterapi\u00ed agonistou GLP-1 (<a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">Semaglutide<\/a>), du\u00e1ln\u00ed agonista GLP-1\/GIP (<a href=\"https:\/\/medsbase.com\/cs\/tirzepatide\/\">Tirzepatide<\/a>), a trojn\u00e1sobn\u00fd agonista GLP-1\/GIP\/glukagonu (<a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a>).<\/li>\n<\/ul>\n<p>Pro \u0161ir\u0161\u00ed kontext o tom, kde se mazdutid \u0159ad\u00ed v r\u00e1mci multiagonistick\u00e9 metabolicko-peptidov\u00e9 krajiny, viz <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> jako trojit\u00fd agonistick\u00fd kompar\u00e1tor, kter\u00fd p\u0159id\u00e1v\u00e1 GIP, <a href=\"https:\/\/medsbase.com\/cs\/tirzepatide\/\">Tirzepatide<\/a> jako alternativn\u00ed du\u00e1ln\u00ed agonista vyu\u017e\u00edvaj\u00edc\u00ed GIP m\u00edsto glukagonu, <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">Semaglutide<\/a> jako z\u00e1kladn\u00ed jednoduch\u00fd agonista, a <a href=\"https:\/\/medsbase.com\/cs\/cagrilintide\/\">Cagrilintide<\/a> jako alternativn\u00ed kombinovan\u00e1 farmakologie na ose amylinu. Prohl\u00e9dn\u011bte si cel\u00fd <a href=\"https:\/\/medsbase.com\/cs\/peptides\/\">katalog v\u00fdzkumn\u00fdch peptid\u016f<\/a> pro p\u0159\u00edbuzn\u00e9 slou\u010deniny.<\/p>\n<h2>Dostupn\u00e9 s\u00edly a koncentrace<\/h2>\n<p>MedsBase nab\u00edz\u00ed Mazdutide ve dvou velikostech lyofilizovan\u00fdch vialek kalibrovan\u00fdch na typick\u00e9 d\u00e9lky v\u00fdzkumn\u00fdch protokol\u016f. Ka\u017ed\u00e9 s\u00edla je dostupn\u00e1 v balen\u00ed po 10 nebo 20 vialk\u00e1ch s \u00fapln\u00fdmi pokyny pro rekonstituci:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">S\u00edla vialky<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typick\u00fd v\u00fdzkumn\u00fd p\u0159\u00edpad u\u017eit\u00ed<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Velikosti balen\u00ed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standardn\u00ed v\u00fdzkumn\u00e1 s\u00edla - pilotn\u00ed d\u00e1vkov\u00e1n\u00ed, protokoly s jednou kohortou, titra\u010dn\u00ed ramena<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protokoly s prodlou\u017een\u00fdm cyklem, studie s v\u00edce kohortami, nejni\u017e\u0161\u00ed cena za mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Ob\u011b s\u00edly jsou stejn\u00e9 chemick\u00e9 formy (lyofilizovan\u00fd pr\u00e1\u0161ek, \u010distota 99 %+ HPLC). Klinick\u00e9 d\u00e1vky ve f\u00e1zi 3 jsou 4\u20139 mg t\u00fddn\u011b, tak\u017ee v\u00fdzkumn\u00e9 vialky s 5 mg nebo 10 mg p\u0159edstavuj\u00ed z\u00e1sobu na jeden a\u017e v\u00edce t\u00fddn\u016f klinicky ekvivalentn\u00edho d\u00e1vkov\u00e1n\u00ed pro in-vivo pr\u00e1ci. Mazdutide je pom\u011brn\u011b vz\u00e1cn\u00fd v\u00fdzkumn\u00fd peptid kv\u016fli strukturn\u00ed slo\u017eitosti a aktivn\u00edmu klinick\u00e9mu v\u00fdvoji, co\u017e se odr\u00e1\u017e\u00ed v cen\u011b za mg ve srovn\u00e1n\u00ed se zaveden\u00fdmi mal\u00fdmi syntetick\u00fdmi peptidy.<\/p>\n<h2>Srovn\u00e1n\u00ed \u2013 Mazdutide vs Retatrutide<\/h2>\n<p>Mazdutide a <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> jsou dva kanonick\u00e9 multiagonistick\u00e9 metabolick\u00e9 peptidy obsahuj\u00edc\u00ed glukagonov\u00fd receptor v sou\u010dasn\u00e9m v\u00fdzkumu. Sd\u00edlej\u00ed z\u00e1klad GLP-1 + glukagon a li\u0161\u00ed se v tom, zda tak\u00e9 aktivuj\u00ed receptor GIP \u2013 Retatrutide ano (trojit\u00fd agonista), Mazdutide ne (du\u00e1ln\u00ed agonista). Toto srovn\u00e1n\u00ed je jedn\u00edm z nej\u010dist\u0161\u00edch v sou\u010dasn\u00e9 metabolicko-peptidov\u00e9 farmakologii, proto\u017ee ramena GLP-1 a glukagonu jsou sd\u00edlena, co\u017e izoluje p\u0159\u00edsp\u011bvek slo\u017eky GIP.<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Krit\u00e9rium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Mazdutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Profil receptoru<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glukagon (du\u00e1ln\u00ed)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + glukagon (trojit\u00fd)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Kostra<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Odvozeno od oxyntomodulinu<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Odvozeno od GIP<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>D\u00e9lka<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~39 aminokyselin<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">39 aminokyselin<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Polo\u010das<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Jednou t\u00fddn\u011b (acylovan\u00fd)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 dn\u00ed<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>V\u00fdvoj\u00e1\u0159 \/ p\u016fvod<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Innovent (IBI362) \/ Eli Lilly (LY3305677)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Eli Lilly (LY3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Regula\u010dn\u00ed status<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Schv\u00e1leno v \u010c\u00edn\u011b (NMPA); ve f\u00e1zi v\u00fdzkumu jinde<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ve f\u00e1zi v\u00fdzkumu (f\u00e1ze 3)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vliv na t\u011blesnou hmotnost<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15\u201317 % (GLORY-1 f\u00e1ze 3, 48 t\u00fddn\u016f)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24 % (f\u00e1ze 2, 48 t\u00fddn\u016f)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typick\u00e1 v\u00fdzkumn\u00e1 t\u00fddenn\u00ed d\u00e1vka<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4\u20139 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201312 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Hlavn\u00ed farmakologick\u00e1 ot\u00e1zka, kter\u00e1 odd\u011bluje tyto dva, je hodnota aktivace receptoru GIP nav\u00edc k GLP-1 + glukagon. \u00da\u010dinek retatrutidu na t\u011blesnou hmotnost ve f\u00e1zi 2 je v\u011bt\u0161\u00ed, co\u017e nazna\u010duje, \u017ee GIP p\u0159in\u00e1\u0161\u00ed zna\u010dn\u00fd benefit, ale selektivn\u011bj\u0161\u00ed du\u00e1ln\u00ed agonistick\u00fd profil mazdutidu vytv\u00e1\u0159\u00ed potenci\u00e1ln\u011b \u010dist\u011bj\u0161\u00ed sign\u00e1l vedlej\u0161\u00edch \u00fa\u010dink\u016f, co\u017e m\u016f\u017ee b\u00fdt d\u016fle\u017eit\u00e9 pro v\u00fdzkum dlouhodob\u00e9 sn\u00e1\u0161enlivosti. Pro farmakologii specifickou pro osu glukagonu je mazdutid \u010dist\u011bj\u0161\u00edm v\u00fdzkumn\u00fdm n\u00e1strojem, proto\u017ee izoluje kombinaci GLP-1 + glukagon bez zmaten\u00ed GIP. Pro v\u00fdzkum maxim\u00e1ln\u00edho \u00fa\u010dinku na t\u011blesnou hmotnost z\u016fst\u00e1v\u00e1 trojit\u00fd agonista <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">retatrutide<\/a> kanonick\u00fdm referen\u010dn\u00edm bodem.<\/p>\n<h2>Skladov\u00e1n\u00ed a rekonstituce<\/h2>\n<p><strong>P\u0159ed rekonstituci:<\/strong> lyofilizovan\u00e9 lahvi\u010dky skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C v p\u016fvodn\u00edm obalu pro kr\u00e1tkodobou pracovn\u00ed z\u00e1sobu. Pro dlouhodob\u00e9 skladov\u00e1n\u00ed v neotev\u0159en\u00e9m stavu zmrazte p\u0159i \u221220 \u00b0C. Lyofilizovan\u00fd mazdutid je stabiln\u00ed v chladni\u010dce a\u017e 24 m\u011bs\u00edc\u016f a p\u0159i \u221220 \u00b0C a\u017e 36 m\u011bs\u00edc\u016f. Vyvarujte se cykl\u016fm zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed lyofilizovan\u00e9ho pr\u00e1\u0161ku.<\/p>\n<p><strong>Postup rekonstituce:<\/strong> injektujte bakteriostatickou vodu po bo\u010dn\u00ed st\u011bn\u011b lahvi\u010dky (ne p\u0159\u00edmo na lyofilizovan\u00fd kol\u00e1\u010d). Pro lahvi\u010dku 5 mg poskytne 2,0 ml bakteriostatick\u00e9 vody pracovn\u00ed koncentraci 2,5 mg\/ml \u2014 0,04 ml dod\u00e1 100 mcg; 0,2 ml dod\u00e1 500 mcg; ~1,6 ml dod\u00e1 klinicky ekvivalentn\u00ed v\u00fdzkumnou d\u00e1vku 4 mg. Jemn\u011b zakru\u017ete \u2014 ne <strong>ne<\/strong> prot\u0159epejte \u2014 a nechte 5\u201310 minut pro \u00fapln\u00e9 rozpu\u0161t\u011bn\u00ed (acylovan\u00e9 peptidy se rozpou\u0161t\u011bj\u00ed pomaleji ne\u017e men\u0161\u00ed nemodifikovan\u00e9 peptidy). Spr\u00e1vn\u011b rekonstituovan\u00fd roztok by m\u011bl b\u00fdt \u010dir\u00fd a bezbarv\u00fd, bez viditeln\u00fdch \u010d\u00e1stic.<\/p>\n<p><strong>Po rekonstituci:<\/strong> Skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C a pou\u017eijte do 30 dn\u016f pro optim\u00e1ln\u00ed stabilitu. Nepou\u017e\u00edvejte zmrazen\u00ed rekonstituovan\u00e9ho roztoku \u2014 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed degraduj\u00ed integritu peptidu. Zlikvidujte jakoukoli lahvi\u010dku vykazuj\u00edc\u00ed z\u00e1kal, sra\u017eeniny nebo zm\u011bnu barvy.<\/p>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3>K \u010demu se Mazdutide pou\u017e\u00edv\u00e1 ve v\u00fdzkumu?<\/h3>\n<p>Mazdutide se pou\u017e\u00edv\u00e1 v laboratorn\u00edm v\u00fdzkumu zam\u011b\u0159en\u00e9m na dvojitou osu agonist\u016f receptor\u016f GLP-1\/glukagonu, regulaci obezity a t\u011blesn\u00e9ho slo\u017een\u00ed, preklinick\u00e9 modely diabetu 2. typu, onemocn\u011bn\u00ed jater MASLD\/MASH, energetick\u00fd v\u00fddej a termogenezi a srovn\u00e1vac\u00ed farmakologii inzretin\u016f s v\u00edce agonisty oproti jednoduch\u00fdm agonist\u016fm GLP-1, dvojit\u00fdm agonist\u016fm GLP-1\/GIP (tirzepatid) a trojit\u00fdm agonist\u016fm GLP-1\/GIP\/glukagon (retatrutid). Je to nejcitovan\u011bj\u0161\u00ed metabolick\u00fd peptid \u010d\u00ednsk\u00e9ho p\u016fvodu v sou\u010dasn\u00e9 literatu\u0159e. V\u00fdzkumn\u00fd mazdutide prod\u00e1van\u00fd zde je <strong>ne<\/strong> schv\u00e1len\u00fd FDA a je dod\u00e1v\u00e1n v\u00fdhradn\u011b pro laboratorn\u00ed v\u00fdzkumn\u00e9 \u00fa\u010dely.<\/p>\n<h3>Jak se Mazdutide li\u0161\u00ed od Semaglutidu?<\/h3>\n<p>Semaglutid je jednoduch\u00fd agonista receptoru GLP-1. Mazdutide p\u0159id\u00e1v\u00e1 agonismus receptoru glukagonu nav\u00edc k GLP-1. P\u0159idan\u00e1 slo\u017eka glukagonu p\u0159isp\u00edv\u00e1 mechanismem energetick\u00e9ho v\u00fddeje \u2014 zv\u00fd\u0161en\u00edm klidov\u00e9ho metabolismu, mobilizac\u00ed jatern\u00edch lipid\u016f a aktivac\u00ed hn\u011bd\u00e9 tukov\u00e9 tk\u00e1n\u011b \u2014 co\u017e agonist\u00e9 pouze GLP-1 neprodukuj\u00ed. Ve srovnateln\u00fdch studi\u00edch f\u00e1ze 3 vykazuje mazdutide o n\u011bco v\u011bt\u0161\u00ed \u00fa\u010dinek na t\u011blesnou hmotnost ne\u017e samotn\u00fd semaglutid (15\u201317 % vs ~15 %), ale hlavn\u00ed praktick\u00fd rozd\u00edl je v mechanismu \u00fabytku hmotnosti: semaglutid p\u0159edev\u0161\u00edm sn\u00ed\u017een\u00edm p\u0159\u00edjmu potravy, mazdutide jak sn\u00ed\u017een\u00edm p\u0159\u00edjmu, tak zv\u00fd\u0161en\u00edm energetick\u00e9ho v\u00fddeje.<\/p>\n<h3>Jak se Mazdutide li\u0161\u00ed od Tirzepatidu?<\/h3>\n<p>Oba jsou dvojit\u00ed agonist\u00e9 inzretin\u016f, ale aktivuj\u00ed r\u016fzn\u00e9 druh\u00e9 receptory. Tirzepatid je GLP-1 + GIP. Mazdutide je GLP-1 + glukagon. Tyto dv\u011b kombinace receptor\u016f produkuj\u00ed kvalitativn\u011b odli\u0161n\u00e9 metabolick\u00e9 profily: GIP (tirzepatid) p\u0159id\u00e1v\u00e1 lipol\u00fdzu adipocyt\u016f v podm\u00ednk\u00e1ch hladov\u011bn\u00ed a m\u00edrn\u00e9 \u00fa\u010dinky na energetick\u00fd v\u00fddej; glukagon (mazdutide) p\u0159id\u00e1v\u00e1 v\u00fdznamn\u00fd energetick\u00fd v\u00fddej a mobilizaci jatern\u00edch lipid\u016f. Tirzepatid m\u00e1 v\u011bt\u0161\u00ed soubor dat z f\u00e1ze 3 a v\u011bt\u0161\u00ed \u00fa\u010dinek na t\u011blesnou hmotnost; mazdutide m\u00e1 jedine\u010dn\u00fd mechanismus pro v\u00fdzkum MASLD\/MASH d\u00edky slo\u017ece jatern\u00edch lipid\u016f \u0159\u00edzen\u00e9 glukagonem.<\/p>\n<h3>Jak se Mazdutide li\u0161\u00ed od Retatrutidu?<\/h3>\n<p>Retatrutid je trojit\u00fd agonista (GLP-1 + GIP + glukagon). Mazdutide je dvojit\u00fd agonista, kter\u00fd sd\u00edl\u00ed ramena GLP-1 + glukagon, ale postr\u00e1d\u00e1 slo\u017eku GIP. \u00da\u010dinek retatrutidu na t\u011blesnou hmotnost ve f\u00e1zi 2 je v\u011bt\u0161\u00ed ne\u017e v\u00fdsledek mazdutidu ve f\u00e1zi 3, co\u017e nazna\u010duje, \u017ee aktivace receptoru GIP p\u0159id\u00e1v\u00e1 v\u00fdznamn\u00fd benefit nav\u00edc k GLP-1 + glukagonu. Pro v\u00fdzkum izoluj\u00edc\u00ed konkr\u00e9tn\u011b kombinaci GLP-1 + glukagon je mazdutide \u010dist\u0161\u00edm n\u00e1strojem, proto\u017ee se vyh\u00fdb\u00e1 zmaten\u00ed GIP; pro maxim\u00e1ln\u00ed \u00fa\u010dinek na t\u011blesnou hmotnost z\u016fst\u00e1v\u00e1 retatrutid kanonickou referenc\u00ed.<\/p>\n<h3>Jak\u00e1 je typick\u00e1 v\u00fdzkumn\u00e1 d\u00e1vka Mazdutidu?<\/h3>\n<p>Publikovan\u00e9 preklinick\u00e9 a klinick\u00e9 v\u00fdzkumn\u00e9 protokoly pou\u017e\u00edvaj\u00ed t\u00fddenn\u00ed subkut\u00e1nn\u00ed d\u00e1vkov\u00e1n\u00ed s titra\u010dn\u00edm sch\u00e9matem za\u010d\u00ednaj\u00edc\u00edm na 1,5\u20133 mg a zvy\u0161uj\u00edc\u00edm se na udr\u017eovac\u00ed d\u00e1vky 4\u20139 mg t\u00fddn\u011b \u2014 rozsah d\u00e1vek pou\u017eit\u00fd ve studi\u00edch f\u00e1ze 3 GLORY-1 a DREAMS-1. L\u00e1hev 5 mg rekonstituovan\u00e1 s 2,0 mL bakteriostatick\u00e9 vody poskytuje 2,5 mg\/mL \u2014 ~1,6 mL odpov\u00edd\u00e1 klinicky ekvivalentn\u00ed v\u00fdzkumn\u00e9 d\u00e1vce 4 mg.<\/p>\n<h3>Je Mazdutide schv\u00e1len FDA?<\/h3>\n<p>Ne. Mazdutide nen\u00ed schv\u00e1len FDA ve Spojen\u00fdch st\u00e1tech, ani nen\u00ed schv\u00e1len EMA nebo MHRA. Byl schv\u00e1len \u010d\u00ednsk\u00fdm NMPA pro lidsk\u00e9 pou\u017eit\u00ed (jeden z prvn\u00edch dualn\u00edch agonist\u016f GLP-1\/glukagonu, kter\u00fd z\u00edskal jak\u00e9koli regula\u010dn\u00ed schv\u00e1len\u00ed na sv\u011bt\u011b), ale pod\u00e1n\u00ed z\u00e1padn\u00edm regula\u010dn\u00edm org\u00e1n\u016fm je st\u00e1le \u010dekaj\u00edc\u00ed nebo prob\u00edhaj\u00edc\u00ed podle sou\u010dasn\u00e9 literatury. Ve\u0161ker\u00fd mazdutide prod\u00e1van\u00fd dodavateli pouze pro v\u00fdzkumn\u00e9 \u00fa\u010dely mimo \u010c\u00ednu je ur\u010den pro laboratorn\u00ed v\u00fdzkum a nem\u011bl by b\u00fdt pod\u00e1v\u00e1n lidem.<\/p>\n<h3>Jak by m\u011bl b\u00fdt Mazdutide skladov\u00e1n?<\/h3>\n<p>Lyofilizovan\u00e9 lahvi\u010dky: kr\u00e1tkodob\u011b skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C, dlouhodob\u011b neotev\u0159en\u00e9 lahvi\u010dky p\u0159i \u221220 \u00b0C. Rekonstituovan\u00fd roztok: skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C, pou\u017eijte do 30 dn\u016f. Rekonstituovan\u00fd roztok nezmrazujte \u2014 mrazic\u00ed cykly degraduj\u00ed peptid. V\u017edy chra\u0148te p\u0159ed p\u0159\u00edm\u00fdm sv\u011btlem.<\/p>\n<h3>Jak rekonstituuji Mazdutide?<\/h3>\n<p>Postupujte podle v\u00fd\u0161e uveden\u00e9ho rekonstitu\u010dn\u00edho postupu. P\u0159idejte bakteriostatickou vodu po stran\u011b lahvi\u010dky (ne p\u0159\u00edmo na lyofilizovanou hmotu), jemn\u011b zakru\u017ete a nechte 5\u201310 minut pro \u00fapln\u00e9 rozpu\u0161t\u011bn\u00ed (acylovan\u00e9 peptidy se rozpou\u0161t\u011bj\u00ed pomaleji ne\u017e men\u0161\u00ed neupraven\u00e9 peptidy). Ne <strong>ne<\/strong> Prot\u0159epejte lahvi\u010dku. Spr\u00e1vn\u011b rekonstituovan\u00fd roztok je \u010dir\u00fd a bezbarv\u00fd. Pro lahvi\u010dku 5 mg + 2,0 mL rozpou\u0161t\u011bdla je pracovn\u00ed koncentrace 2,5 mg\/mL.<\/p>\n<h3>Jak\u00e9 s\u00edly nab\u00edz\u00ed MedsBase?<\/h3>\n<p>MedsBase nab\u00edz\u00ed Mazdutide v lyofilizovan\u00fdch lahvi\u010dk\u00e1ch 5 mg a 10 mg. Ka\u017ed\u00e1 s\u00edla je dostupn\u00e1 v balen\u00ed po 10 nebo 20 lahvi\u010dk\u00e1ch. V\u0161echny lahvi\u010dky jsou dod\u00e1v\u00e1ny s \u010distotou 99 %+ HPLC a certifik\u00e1tem anal\u00fdzy na vy\u017e\u00e1d\u00e1n\u00ed.<\/p>\n<h3>Pro\u010d Mazdutide aktivuje tak\u00e9 receptor glukagonu?<\/h3>\n<p>Strukturn\u00ed inspirac\u00ed pro mazdutide je oxyntomodulin, endogenn\u00ed 37-aminokyselinov\u00fd produkt zpracov\u00e1n\u00ed preproglukagonu ve st\u0159evn\u00edch L-bu\u0148k\u00e1ch, kter\u00fd p\u0159irozen\u011b aktivuje jak receptory GLP-1, tak glukagonu. Dvoj\u00ed farmakologie tedy nen\u00ed um\u011ble vytvo\u0159ena \u2014 d\u011bd\u00ed se z p\u0159irozen\u00e9 struktury oxyntomodulinu. Co je um\u011ble upraveno, je odolnost v\u016f\u010di \u0161t\u011bpen\u00ed DPP-4 a acylace mastn\u00fdmi kyselinami, kter\u00e1 zaji\u0161\u0165uje polo\u010das \u00fa\u010dinku na jeden t\u00fdden, spolu s jemn\u00fdm lad\u011bn\u00edm relativn\u00ed potence receptor\u016f GLP-1 versus glukagonu ve prosp\u011bch \u010dist\u00e9ho \u00fa\u010dinku sni\u017euj\u00edc\u00edho hladinu gluk\u00f3zy.<\/p>\n<h3>Zp\u016fsobuje glukagonov\u00e1 slo\u017eka hyperglyk\u00e9mii?<\/h3>\n<p>Toto je klasick\u00fd \u201cglukagonov\u00fd paradox\u201d ve v\u00fdzkumu dualn\u00edch agonist\u016f. Glukagon s\u00e1m o sob\u011b zvy\u0161uje hladinu gluk\u00f3zy stimulac\u00ed jatern\u00edho v\u00fddeje gluk\u00f3zy, co\u017e by diabetes sp\u00ed\u0161e zhor\u0161ilo ne\u017e zlep\u0161ilo. U mazdutidu p\u0159eva\u017euje slo\u017eka GLP-1 t\u00edm, \u017ee dominantn\u011b sni\u017euje hladinu gluk\u00f3zy p\u016fsoben\u00edm na inzul\u00edn a potla\u010den\u00ed glukagonu v beta- a alfa-bu\u0148k\u00e1ch, zat\u00edmco slo\u017eka glukagonu zachov\u00e1v\u00e1 v\u00fdhody mobilizace lipid\u016f a v\u00fddeje energie. Publikovan\u00fd v\u00fdzkum potvrzuje \u010dist\u00e9 sn\u00ed\u017een\u00ed hladiny gluk\u00f3zy navzdory aktivaci receptoru glukagonu, co\u017e demonstruje, \u017ee upraven\u00fd pom\u011br potence GLP-1 k glukagonu dosahuje po\u017eadovan\u00e9 rovnov\u00e1hy.<\/p>\n<h3>Zp\u016fsobuje Mazdutide ve v\u00fdzkumu vedlej\u0161\u00ed \u00fa\u010dinky?<\/h3>\n<p>Nejkonzistentn\u011bj\u0161\u00edm zji\u0161t\u011bn\u00edm jsou gastrointestin\u00e1ln\u00ed \u00fa\u010dinky, podobn\u011b jako u jin\u00fdch peptid\u016f osy GLP-1 \u2014 nevolnost, p\u0159echodn\u00e9 potla\u010den\u00ed chuti k j\u00eddlu a opo\u017ed\u011bn\u00e9 vyprazd\u0148ov\u00e1n\u00ed \u017ealudku jsou z\u00e1visl\u00e9 na d\u00e1vce a maj\u00ed tendenci se sni\u017eovat b\u011bhem 4\u20138 t\u00fddn\u016f kontinu\u00e1ln\u00edho d\u00e1vkov\u00e1n\u00ed, jak se vyv\u00edj\u00ed tachyfylaxe receptor\u016f. Mezi n\u00e1lezy souvisej\u00edc\u00ed se slo\u017ekou glukagonu pat\u0159\u00ed m\u00edrn\u00e9 zv\u00fd\u0161en\u00ed klidov\u00e9 srde\u010dn\u00ed frekvence a (vz\u00e1cn\u011b) p\u0159echodn\u00e9 \u00fa\u010dinky na krevn\u00ed tlak. Dlouhodob\u00e1 data o bezpe\u010dnosti se st\u00e1le shroma\u017e\u010fuj\u00ed ze studi\u00ed f\u00e1ze 3 v \u010c\u00edn\u011b a postmarketingov\u00e9ho sledov\u00e1n\u00ed.<\/p>\n<h3>Jak\u00fd je polo\u010das Mazdutidu?<\/h3>\n<p>Mazdutide m\u00e1 plazmatick\u00fd polo\u010das dostate\u010dn\u00fd pro podporu t\u00fddenn\u00edho subkut\u00e1nn\u00edho d\u00e1vkov\u00e1n\u00ed v klinick\u00e9m v\u00fdzkumu, dosa\u017een\u00fd reverzibiln\u00ed vazbou na s\u00e9rov\u00fd albumin prost\u0159ednictv\u00edm acylovan\u00e9ho mastn\u00e9ho kyselinov\u00e9ho \u0159et\u011bzce. P\u0159esn\u00fd polo\u010das je o n\u011bco krat\u0161\u00ed ne\u017e u semaglutidu (~165 hodin), ale ve stejn\u00e9m re\u017eimu t\u00fddenn\u00edho d\u00e1vkov\u00e1n\u00ed. D\u00e1vkovac\u00ed sch\u00e9ma a design klinick\u00fdch studi\u00ed s n\u00edm zach\u00e1zej\u00ed jako s pln\u011b t\u00fddenn\u00edm p\u0159\u00edpravkem.<\/p>\n<h3>Jak dlouho trv\u00e1, ne\u017e se \u00fa\u010dinky Mazdutidu projev\u00ed v preklinick\u00e9m v\u00fdzkumu?<\/h3>\n<p>Akutn\u00ed farmakodynamick\u00e9 \u00fa\u010dinky na gluk\u00f3zovou toleranci a vyprazd\u0148ov\u00e1n\u00ed \u017ealudku jsou detekovateln\u00e9 ji\u017e b\u011bhem n\u011bkolika hodin po prvn\u00ed d\u00e1vce. \u00da\u010dinky na t\u011blesnou hmotnost u ob\u00e9zn\u00edch hlodavc\u016f se obvykle st\u00e1vaj\u00ed statisticky v\u00fdznamn\u00fdmi po 1\u20132 t\u00fddnech t\u00fddenn\u00edho d\u00e1vkov\u00e1n\u00ed a d\u00e1le se zvy\u0161uj\u00ed po dobu 8\u201316 t\u00fddn\u016f. Maxim\u00e1ln\u00ed \u00fa\u010dinek na t\u011blesn\u00e9 slo\u017een\u00ed se rozv\u00edj\u00ed b\u011bhem 16\u201324 t\u00fddn\u016f kontinu\u00e1ln\u00edho d\u00e1vkov\u00e1n\u00ed, co\u017e odpov\u00edd\u00e1 trajektorii u lid\u00ed ve f\u00e1zi 3 studie GLORY-1.<\/p>\n<h3>Mohu si objednat Mazdutide s mezin\u00e1rodn\u00ed dopravou?<\/h3>\n<p>Ano. MedsBase expeduje Mazdutide do cel\u00e9ho sv\u011bta prost\u0159ednictv\u00edm na\u0161\u00ed specializovan\u00e9 s\u00edt\u011b pro dopravu peptid\u016f. Objedn\u00e1vky obsahuj\u00edc\u00ed pouze peptidy kvalifikuj\u00ed pro na\u0161i samostatnou slu\u017ebu peptidov\u00e9 dopravy. V\u0161echny objedn\u00e1vky jsou expedov\u00e1ny v termostabiln\u00edm balen\u00ed s pln\u00fdm sledov\u00e1n\u00edm a jsou kryty na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\">Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Dal\u0161\u00ed peptidy pro v\u00fdzkum metabolismu, t\u011blesn\u00e9ho slo\u017een\u00ed a multiagonist\u016f<\/h2>\n<ul>\n<li><a href=\"\/cs\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Trojit\u00fd agonista GLP-1\/GIP\/glukagon \u2014 p\u0159id\u00e1v\u00e1 GIP k receptorov\u00e9mu profilu mazdutidu<\/li>\n<li><a href=\"\/cs\/tirzepatide\/\"><strong>Tirzepatide<\/strong><\/a> \u2014 Dualn\u00ed agonista GLP-1\/GIP \u2014 alternativn\u00ed dualn\u00ed agonista vyu\u017e\u00edvaj\u00edc\u00ed GIP m\u00edsto glukagonu<\/li>\n<li><a href=\"\/cs\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Jednoduch\u00fd agonista GLP-1 \u2014 kanonick\u00fd z\u00e1kladn\u00ed kompar\u00e1tor<\/li>\n<li><a href=\"\/cs\/cagrilintide\/\"><strong>Cagrilintide<\/strong><\/a> \u2014 Analog amylinu \u2014 alternativn\u00ed p\u0159\u00edstup kombinovan\u00e9 farmakologie (CagriSema)<\/li>\n<li><a href=\"\/cs\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 Analog GHRH \u2014 v\u00fdzkum viscer\u00e1ln\u00edho tuku<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Dal\u0161\u00ed \u010dten\u00ed<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Prozkoumejte krajinu metabolick\u00fdch peptid\u016f s multiagonisty<\/strong><\/p>\n<p style=\"margin: 0;\">Prohl\u00e9dn\u011bte si celou <a href=\"https:\/\/medsbase.com\/cs\/peptides\/\"><strong>katalog v\u00fdzkumn\u00fdch peptid\u016f<\/strong><\/a>, v\u010detn\u011b p\u0159\u00edbuzn\u00fdch slou\u010denin jako <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> (trojit\u00fd agonista), <a href=\"https:\/\/medsbase.com\/cs\/tirzepatide\/\">Tirzepatide<\/a> (dvojit\u00fd agonista GLP-1\/GIP), a <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">Semaglutide<\/a> (jednoduch\u00fd agonista). Srovn\u00e1vac\u00ed pr\u016fvodce: <a href=\"https:\/\/medsbase.com\/cs\/retatrutide-vs-tirzepatide\/\">Retatrutid vs Tirzepatid \u2014 trojit\u00fd vs dvojit\u00fd agonista<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Dvojit\u00fd agonista GLP-1 + glukagonov\u00e9ho receptoru<br \/>\n\u2705 Odvozeno od oxyntomodulinov\u00e9ho skeletu (IBI362 \/ LY3305677)<br \/>\n\u2705 P\u0159id\u00e1v\u00e1 mechanismus v\u00fddeje energie nad r\u00e1mec samotn\u00e9ho GLP-1<br \/>\n\u2705 Schv\u00e1leno v \u010c\u00edn\u011b; ve v\u00fdzkumu na Z\u00e1pad\u011b<br \/>\n\u2705 D\u00e1vkov\u00e1n\u00ed jednou t\u00fddn\u011b<\/p>\n<p><strong>Mazdutide<\/strong> obsahuje syntetickou peptidovou slou\u010deninu.<\/p>","protected":false},"featured_media":70965,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6285,5441],"class_list":{"0":"post-70754","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptides","7":"product_tag-mazdutide","8":"product_tag-peptide","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/70754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=70754"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/70965"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=70754"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=70754"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=70754"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=70754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}